NASDAQ: PRTC - PureTech Health plc

六个月盈利: -14.52%
股息率: 0.00%
部门: Healthcare

促销时间表 PureTech Health plc

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 PureTech Health plc

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies.

更多详情
It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2020-11-16
ISIN US7462371060
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.puretechhealth.com
Цена ао 16.75
每日价格变化: -0.4407% (17.7)
每周价格变化: +5.47% (16.7088)
每月价格变化: -6.71% (18.89)
3个月内价格变化: -9.68% (19.51)
六个月内的价格变化: -14.52% (20.615)
每年价格变化: -38.17% (28.5)
3年内价格变化: -38.77% (28.78)
年初以来价格变化: -4.54% (18.46)
所有参数

低估

姓名 意义 年级
P/S 211.58 1
P/BV 1.24 9
P/E 0 0
EV/EBITDA -3.8 0
全部的: 3.63

效率

姓名 意义 年级
ROA, % -9.47 0
ROE, % -14.16 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0.0657

责任

姓名 意义 年级
Debt/EBITDA -0.1806 10
全部的: 9.6

成长冲动

姓名 意义 年级
盈利能力 Revenue, % -61.72 0
盈利能力 Ebitda, % -87.75 0
盈利能力 EPS, % -101.65 0
全部的: 0
更多详情

机构 体积 分享, %
Pentwater Capital Management LP 10244 0.04
Tower Research Capital LLC (TRC) 43 0
UBS Group AG 20 0

ETF分享, %本年盈利能力, %股息, %
Amplify BlueStar Israel Technology ETF 0.30643 20.42 0.47569
Invesco Global Listed Private Equity ETF 0.29338 29.43 3.4983
Dimensional International Small Cap ETF 0.02653 5.69 3.34747
SPDR S&P International Small Cap ETF 0.0233 8.94 3.10348
Schwab International Small-Cap Equity ETF 0.0133 10.07 3.20638
SPDR Portfolio Europe ETF 0.00347 8.94 3.66537
Dimensional International Core Equity 2 ETF 0.00136 6.52 3.69996
Avantis International Equity ETF 0.00099 6.46 3.80856
Dimensional International Core Equity Market ETF 0.00032 13.09 3.48343
Vanguard FTSE All-World ex-US Small-Cap ETF 0 9.39 3.09932
Vanguard ESG International Stock ETF 0 6.39 3.07501
0.0611.393.13



导师 职称 支付 出生年份
Ms. Daphne Zohar Founder, Senior Advisor & Board Observer 3.99M 1971 (54 年)
Dr. Bharatt M. Chowrira J.D., Ph.D. CEO & Executive Director 2.19M 1965 (60 年)
Dr. David R. Elmaleh Ph.D. Co-Founder & Senior Advisor N/A 1948 (77 年)
Ms. Allison Mead Talbot Head of Communications & Investor Relations N/A
Mr. Spencer Ball Senior Vice President of Human Resources N/A
Dr. Eric Elenko Ph.D. Co-Founder & President N/A 1973 (52 年)
Mr. Eric Green M.B.A. Chief Operating Officer N/A
Mr. Charles Sherwood III, J.D., Ph.D. General Counsel & Company Secretary N/A
Dr. Robert S. Langer Jr., Ph.D., ScD Co-Founder & Non-Executive Director 1949 (76 年)
Mr. Michael Inbar CPA, M.B.A. Senior Vice President of Finance

地址: United States, Boston. MA, 6 Tide Street - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.puretechhealth.com